Decreased DNA Damage and Improved p53 Specificity of RITA Analogs

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Reactivating the p53 tumor suppressor is a promising cancer treatment strategy.
• The small molecule RITA induces p53-dependent apoptosis but also causes DNA damage via SULT1A1 modification.
• Synthetic modifications aim to create RITA analogs with improved specificity and reduced toxicity.

Purpose of the Study:

• To investigate if RITA analogs NSC777196 and NSC782846 can induce p53-dependent apoptosis without SULT1A1-mediated DNA damage.
• To evaluate the potential of these analogs as targeted cancer therapeutics.

Main Methods:

• Synthesis and chemical modification of RITA analogs.
• Assessing p53-dependent apoptosis induction in cancer cells.
• Measuring DNA damage and RNA polymerase II inhibition.
• Analyzing p53-regulated gene expression.

Main Results:

• NSC782846, but not NSC777196, induced p53-regulated genes and cancer cell death.
• NSC782846 achieved this via p53 reactivation without causing DNA damage or inhibiting RNA polymerase II.
• This suggests a dissociation between p53 reactivation and genotoxicity for NSC782846.

Conclusions:

• NSC782846 demonstrates a potential for p53-dependent cancer cell killing without genotoxicity.
• This study provides a framework for designing next-generation RITA analogs with enhanced specificity.
• Findings may accelerate the clinical translation of p53-targeting cancer drugs.